ESG Integration in Investment Due Diligence | LeverVenture

Most ESG diligence run on healthcare and life sciences companies measures the wrong things. It imports a checklist built for industrial and consumer businesses — carbon disclosure, board gender composition, a supplier code of conduct — and applies it to a diagnostics company or a clinical-stage biopharma, where none of those are the risks that actually determine whether the business is durable. Materiality in this sector runs through clinical ethics, data privacy, pricing and access, supply dependency, and workforce practice specific to clinical labor. A diligence process that does not test those is not under-scoping ESG. It is measuring the wrong sector entirely and calling it thoroughness.

The distinction that matters is between materiality-driven diligence and disclosure-driven diligence. Disclosure-driven diligence asks whether a company has policies and can produce documents. Materiality-driven diligence asks whether the specific things that would actually impair value — a mishandled trial, a data breach involving patient records, a single-source supplier that can halt manufacturing — are managed with the rigor their consequences deserve. A company can pass the first kind of review with a well-organized policy binder and still be carrying the second kind of risk undetected.

01What is genuinely material in life sciences and healthcare

Six areas recur across the sector, though which ones dominate depends heavily on business model:

• Clinical trial diversity and ethics. Enrollment practices, informed consent quality, and site oversight are not compliance formalities — they determine whether a trial's results will be defensible to regulators and payers, and whether the company can be trusted with the next one.
• Patient data privacy and security. A breach involving protected health information carries regulatory, reputational, and commercial consequences that are typically larger and faster-moving than a comparable breach at a non-healthcare company.
• Access and pricing policy. How a company prices and where it chooses to sell shapes its regulatory and reimbursement exposure for the life of the product, not just its near-term revenue.
• Supply chain and single-source dependency. Active pharmaceutical ingredients, specialized components, and contract manufacturing relationships concentrated in one supplier or one geography are an operating risk with a direct line to revenue continuity.
• Clinician and healthcare workforce practice. Licensure, credentialing, supervision ratios, and burnout in a clinically staffed business are workforce issues with regulatory teeth that a generic labor-practices questionnaire will not surface.
• Governance quality at founder-led companies. Board independence, related-party transactions, and whether clinical or commercial decisions can be overridden by a single founder are governance questions that matter more, not less, at a smaller company where formal structure is still being built.

Which of these dominates depends on the company. A diagnostics business lives or dies on data privacy and supply dependency. A clinical-stage biopharma lives or dies on trial ethics and governance. A digital health platform serving clinicians lives or dies on workforce practice and data security together. Applying the same weighting to all three is the specific failure this piece is naming.

02Materiality differs by sub-sector — the framework should too

Independent accounting-standards work on sustainability disclosure has reached the same conclusion from a different direction: material ESG topics are not uniform even within healthcare. Supply chain management is treated as material for biopharmaceutical and medical equipment businesses in a way it typically is not for a pure clinical-services company; billing and pricing transparency is weighted differently across care delivery, distribution, and device manufacturing. A diligence framework that does not vary by sub-sector is working against evidence that materiality itself varies by sub-sector.

03Box-ticking versus materiality: what the diligence process should ask

A box-ticking review asks whether a policy exists. A materiality-driven review asks a sharper question for each of the six areas above: what is the specific mechanism by which this risk could impair enterprise value, and what evidence — not what policy — demonstrates it is controlled. That reframing changes what diligence teams request. Instead of a supplier code of conduct, they ask for concentration data on single-source inputs. Instead of a data-privacy policy, they ask for the architecture that separates identified patient data from the systems a commercial team can access.

A policy document proves a company knows what good practice looks like. It proves nothing about whether the company practices it.

04Governance at founder-led companies deserves its own line of inquiry

Growth-stage healthcare companies are disproportionately founder-led, and founder-led governance is not inherently a red flag — concentrated authority is often exactly what let the company move fast enough to reach this stage. The diligence question is whether that authority has any structural check on the decisions most likely to create liability: clinical protocol changes, pricing decisions with regulatory exposure, and related-party transactions. A board that exists on paper but has never overruled a founder is a governance structure that has not yet been tested, and diligence should treat it as unproven rather than assume it will hold under pressure.

05What this means for a diligence process

A materiality-driven ESG process in healthcare and life sciences starts from the business model, not from a template. It identifies which two or three of the six areas above are load-bearing for the specific company, requests operating evidence rather than policy documents for those, and treats the rest as lower priority rather than pretending to weigh everything equally. That is a harder process to run than a standardized checklist, and it is the only version of ESG diligence that actually tells an investor something about durability rather than paperwork.

It also produces a different set of post-close priorities. A box-ticking process ends at close, because its deliverable was a completed checklist. A materiality-driven process hands the investment team a short list of specific risks to monitor — a supplier concentration to diversify, a data architecture gap to close, a governance check to install — which is a far more useful inheritance than a binder confirming that policies exist. The diligence process and the value-creation plan should be the same document, not two separate exercises that happen to be filed in the same deal room.

Related reading: the ROI² investment philosophy sets out the broader argument that impact and return are not in tension. evaluating founder-led management teams and the precision medicine investment landscape extend the governance and sub-sector questions raised here.

Nothing in this piece is investment, legal, tax or accounting advice, and nothing in it is an offer to sell or a solicitation of an offer to buy any security.